Compass Therapeutics, Inc. 8-K

What Happened
Compass Therapeutics, Inc. (CMPX) issued a press release on January 6, 2026 providing a corporate update and disclosing a preliminary estimate that its cash, cash equivalents and marketable securities totaled approximately $209 million as of December 31, 2025. The company filed this information on Form 8‑K (Items 2.02 and 8.01). The amount is unaudited, preliminary and subject to completion of financial close procedures, and therefore may differ materially from the audited amounts reported in the company’s year‑end financial statements.

Key Details

• Date of disclosure: January 6, 2026 (press release attached as Exhibit 99.1).
• Preliminary cash balance: approximately $209 million as of December 31, 2025.
• Status: Unaudited and preliminary; subject to completion of financial closing procedures and possible material change.
• Filing items: Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).

Why It Matters
A company’s cash, cash equivalents and marketable securities balance is a direct indicator of liquidity and ability to fund operations, R&D and clinical programs without immediate financing. For investors, the preliminary $209M figure provides an early view of Compass’s financial condition heading into 2026—but because the number is unaudited and may change, investors should wait for the company’s audited year‑end financial statements (e.g., Form 10‑K) for final figures before drawing firm conclusions.